EZH2 and cancer: We identified a novel cancer driver lncRNA, PRADX that recruits PRC2/DDX5 complex by interacting with EZH2 and promotes NF-κB activity via UBXN1 suppression, which in turn contributes to GBM and COAD tumorigenesis.